US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Genomics Immunology and Healthcare ETF

39.67

-0.4100-1.02%

Volume:143.91K

Turnover:5.68M

Market Cap:247.94M

PE:- -

High:39.84

Open:39.76

Low:39.00

Close:40.08

52wk High:40.86

52wk Low:22.12

Shares:6.25M

Float Shares:6.25M

Volume Ratio:1.29

T/O Rate:2.30%

Dividend:0.28

Dividend Rate:0.71%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Crinetics nears shareholder vote on Vertex merger

Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Moderna Expands Respiratory Vaccine Pipeline With New RSV/hMPV Trial in Older Adults

PDS Biotech Reports Second Quarter 2026 Financial Results

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding

Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks

Moderna Inc. Stock Rises 5.1%, Outperforms Peers

Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says

MT Newswires Live

Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers

Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/IDNA/news?page=11"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","market":"US","secType":"STK","nameCN":"iShares Genomics Immunology and Healthcare ETF","latestPrice":39.67,"timestamp":1787601600000,"preClose":40.08,"halted":0,"volume":143908,"delay":0,"changeRate":-0.010229540918163587,"floatShares":6250000,"shares":6250000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.41,"latestTime":"08-25 06:14:13 EDT","open":39.76,"high":39.84,"low":39,"amount":5676438.10828,"amplitude":0.020958,"askPrice":45.35,"askSize":100,"bidPrice":34.46,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787664600000},"marketStatusCode":1,"adr":0,"exchange":"ARCA","adjPreClose":39.67,"sharesOutstanding":5100000,"nav":40.06069,"aum":250379312.5,"dividendRate":0.007101,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":39.67,"preClose":39.67,"latestTime":"19:30 EDT","volume":58,"amount":2282.47,"timestamp":1787614204422,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.289403465846127,"impliedVol":0.0476,"impliedVolPercentile":0.016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDNA\",,,,,undefined,":{"symbol":"IDNA","floatShares":6250000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.289403465846127,"shares":6250000,"dividePrice":0.2817,"high":39.84,"amplitude":0.020958,"preClose":40.08,"low":39,"week52Low":22.12,"pbRate":"--","week52High":40.8599,"institutionHeld":0,"latestPrice":39.67,"eps":0,"divideRate":0.007101,"volume":143908,"delay":0,"ttmEps":0,"open":39.76,"prevYearClose":26.19,"prevWeekClose":40.08,"prevMonthClose":32.33,"prevQuarterClose":33.75,"fiveDayClose":35.86,"twentyDayClose":32.24,"sixtyDayClose":30.08},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDNA\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"IDNA","amount":0.125421,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2025-12-16","symbol":"IDNA","amount":0.155456,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-06-16","symbol":"IDNA","amount":0.152909,"announcedDate":"2025-06-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-16","defaultRemindTime":1750080600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-20","payableDate":"2025-06-16","currency":"USD","dateTimestamp":1750046400000,"payDate":"2025-06-20"},{"date":"2024-12-17","symbol":"IDNA","amount":0.11105,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2024-06-11","symbol":"IDNA","amount":0.11144,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-11","defaultRemindTime":1718112600000,"name":"iShares Genomics Immunology and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-06-17","payableDate":"2024-06-11","currency":"USD","dateTimestamp":1718078400000,"payDate":"2024-06-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDNA\",market:\"US\",,,undefined,":[{"executeDate":"2019-12-16","recordDate":"2019-12-17","paymentDate":"2019-12-20","value":0.237063,"currency":"USD"},{"executeDate":"2020-06-15","recordDate":"2020-06-16","paymentDate":"2020-06-19","value":0.083667,"currency":"USD"},{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-18","value":0.036209,"currency":"USD"},{"executeDate":"2021-06-10","recordDate":"2021-06-11","paymentDate":"2021-06-16","value":0.052145,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-17","value":0.256358,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDNA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDNA\",pageSize:20,pageCount:11,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2659144409","title":"Crinetics nears shareholder vote on Vertex merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144409","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144409?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:21","pubTimestamp":1786713691,"startTime":"0","endTime":"0","summary":"An update from Crinetics Pharmaceuticals ( ($CRNX) ) is now available. On July 6, 2026, Crinetics Pharmaceuticals agreed to merge with Vertex Pharm...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crinetics-nears-shareholder-vote-on-vertex-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crinetics-nears-shareholder-vote-on-vertex-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU2237438978.USD","TBXU","IE00B894F039.SGD","BBH","LU2324357040.USD","MRGR","VERX","IBB","LU1093756168.USD","LU1674673691.USD","LU2462157665.USD","LU2362541513.USD","IE00B4R5TH58.HKD","GNMX","LU0256863811.USD","LU0058720904.USD","IBBQ","LU1674673428.USD","LU1778281490.HKD","LU1069344957.HKD","LU1815336091.USD","LU2362541273.HKD","IE00B19Z9P08.USD","BK4139","PBE","IE00BFTCPJ56.SGD","LU2089984988.USD","IE0009355771.USD","IE00B19Z9Z06.USD","LU1559883803.SGD","LU1585245621.USD","IE00BJJMRZ35.SGD","SG9999013999.USD","VRTX","LU0109394709.USD","LU2362540622.SGD","IE00BZ9MQY76.HKD","IDNA","SGXZ57979304.SGD","IE00BJT1NW94.SGD","SG9999001176.USD","RSBA","IE00B19Z3B42.SGD","BIB","LU0320765992.SGD","LU0566484027.USD","LU0889565916.HKD","LU0079474960.USD","SG9999001176.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659141595","title":"Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign","url":"https://stock-news.laohu8.com/highlight/detail?id=2659141595","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659141595?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:00","pubTimestamp":1786708800,"startTime":"0","endTime":"0","summary":"- Completed quarter with $26.9 million in cash and restricted cash - Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP companion diagnostic i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345276/0/en/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-the-phase-3-ready-stenoparib-manufacturing-campaign.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4539","LENZ","BK4503","API","BK4023","ALLR","PLTM","CLIA","IDNA","BK4139","BK4551","CDMO","BK4007","NVIB","BMED","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659450421","title":"Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2659450421","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659450421?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regu","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/14/3345223/24675/en/fate-therapeutics-initiates-potentially-registrational-reclaim-ln-clinical-trial-of-ft819-for-the-treatment-of-lupus-nephritis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","LABU","BK4022","FATE","BK4230","NVIB","BMED","BK4077","SLE","HYLG","MEDX","CAR","GDOC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659195237","title":"Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2659195237","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659195237?lang=en_us&edition=fundamental","pubTime":"2026-08-14 05:02","pubTimestamp":1786654920,"startTime":"0","endTime":"0","summary":"Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regenerationContinued favorable safety and tolerab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3345007/0/en/satellos-reports-second-quarter-2026-financial-results-and-highlights-company-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","HYLG","BMED","IDNA","MSLE","IND","NVIB","PRGS","MEDX","LU2065732104.USD","BK4139","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659627661","title":"CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659627661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659627661?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344920/0/en/camp4-reports-second-quarter-2026-financial-results-and-corporate-highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","NVIB","GDOC","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162993","title":"Press Release: Invivyd Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162993","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162993?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"-- Achieved Q2 2026 PEMGARDA  net product revenue of $14.3. million, representing 21% growth versus Q2 2025 net product revenue of. -- Completed rapid enrollment in VYD2311 DECLARATION clinical trial. expansion cohort and LIBERTY clinical trial, driven by strong subject. -- DECLARATION pivotal clinical trial enrollment is complete; the ongoing. study is approaching its planned analysis, and in lieu of a Q2 2026. quarterly earnings call, Invivyd plans to hold an investor call post. -- Strong balance sheet with Q2 2026 ending cash and cash equivalents of. $160.1 million anticipated to provide runway through DECLARATION pivotal. data readout and support potential commercial launch readiness for. 30, 2026, compared to $11.8 million in for the quarter ended June 30,-- In July 2026, Invivyd announced receipt of twelve months' advanced notice. of emergency use authorization  termination for PEMGARDA and that. the company is in dialogue with the U.S. Food and Drug Administration.  about approp","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4551","BK4535","BK4585","BK4539","IVVD","MEDX","NVIB","BK4568","GDOC","R","BNTX","IDNA","BK4022","HYLG","BK4548","IND","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","FBT","BK4195","CNCR","BK4211","MEDX","CAR","GNOM","CRBU","SYNB","BK4161","NVIB","BK4539","LFSC","GDOC","LD","HYLG","BK4585","CR","BK4022","IDNA","ORR","PFS","IBBQ","TBXU","BK4230","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162812","title":"Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162812","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162812?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:01","pubTimestamp":1786651260,"startTime":"0","endTime":"0","summary":"Following the observation of multiple complete responses, Elicio plans to initiate a Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344883/0/en/elicio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IDNA","ELTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659166082","title":"Moderna Expands Respiratory Vaccine Pipeline With New RSV/hMPV Trial in Older Adults","url":"https://stock-news.laohu8.com/highlight/detail?id=2659166082","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659166082?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:30","pubTimestamp":1786638638,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) announced an update on their ongoing clinical study. ModernaTX, Inc. has launched a new early-stage trial called “A Phase 1, Random...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moderna-expands-respiratory-vaccine-pipeline-with-new-rsv-hmpv-trial-in-older-adults?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moderna-expands-respiratory-vaccine-pipeline-with-new-rsv-hmpv-trial-in-older-adults?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGHT","BK4501","BK4585","BK4534","BK4551","BK4532","GNOM","BK4139","IDNA","MRNX","BK4533","BK4588","BK4568","WDNA","BK4548","MRNA","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152369","title":"PDS Biotech Reports Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152369","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152369?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Aug.  13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/13/3344498/37149/en/pds-biotech-reports-second-quarter-2026-financial-results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4581","BK4092","NVIB","PDS","XBI","HYLG","IDNA","ORR","MEDX","GDOC","BK4588","BK4195","BK4585","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659130742","title":"Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130742","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130742?lang=en_us&edition=fundamental","pubTime":"2026-08-13 17:39","pubTimestamp":1786613984,"startTime":"0","endTime":"0","summary":"BUZZ-Cullinan climbs as lung cancer drug meets late-stage trial goal** Shares of Cullinan TherapeuticsCGEM.Orise 6% to $20.77 premarket** Cullinan says its experimental cancer drug, zipalertinib, when","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL4N44A0QA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","CGEM","IE0009354923.USD","IDNA","LU0109394709.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","CANC","IE00B4R5TH58.HKD","BBH","LU0320765992.SGD","RVMD","PTH","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659613658","title":"CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2659613658","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659613658?lang=en_us&edition=fundamental","pubTime":"2026-08-13 14:12","pubTimestamp":1786601532,"startTime":"0","endTime":"0","summary":"Amur Minerals ( ($GB:CRTX) ) has shared an announcement. CRISM Therapeutics has completed the Site Initiation Visit at its lead NHS clinical trial ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crism-therapeutics-clears-key-step-to-begin-phase-ii-glioblastoma-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","LENZ","BK4139","IDNA","BK4007","MEDX","NVIB","BK4539","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1808992512.USD","LU0700851271.USD","LU0348766576.USD","XBIX","LU1251922891.USD","LU2242644610.SGD","IBRN","LU2328871848.SGD","LU1979443071.USD","IDNA","BBC","LU1934453819.USD","BMED","WX","PSIL","BK1583","BK1576","LU1969619763.USD","SMCO","LU1719994722.HKD","603259","PSCH","LU0348767384.USD","161027","IE00B5MMRT66.SGD","APXH","02359","SURI","LU2495084118.USD","LU0708995583.HKD","LU0052750758.USD","LFSC","LU1997245094.SGD","LU2125910500.SGD","LU0456842615.SGD","BK1141","IE00B543WZ88.USD","CXO","LU1303224171.USD","LU2045819591.USD","LU1046422090.SGD","LU0320764599.SGD","IE00BPRC5H50.USD","LU0611395673.USD","BK0216","LU2488822045.USD","MEDI","LU1997244956.HKD","FHLC","LU1997245177.USD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111112440","title":"Bank of America Securities Raises Targets for Chinese CXO Firms on Strong Biotech Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=1111112440","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111112440?lang=en_us&edition=fundamental","pubTime":"2026-08-13 10:35","pubTimestamp":1786588544,"startTime":"0","endTime":"0","summary":"A report from Bank of America Securities indicates that Chinese CRO/CDMO companies are poised to benefit from robust first-half funding in the global and Chinese biotech sectors, along with active...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348766576.USD","SMCO","CXO","LU0417516738.SGD","LU0588546209.SGD","WX","LU0128526141.USD","LU1997245177.USD","LU0611395673.USD","LU0819121731.USD","LU1979443071.USD","LU0307460666.USD","KURE","BK1576","LU2328871848.SGD","LU0572944931.SGD","PSIL","LU0359201612.USD","IE00B0JY6N72.USD","161027","LU1997244956.HKD","LU1934453819.USD","LU0051755006.USD","LU0708995583.HKD","BK1610","LU2045819591.USD","BMED","MEDI","LU3063872942.SGD","LU0856984785.SGD","02269","LU2125910500.SGD","LU1770034418.SGD","SG9999002463.SGD","IDNA","BK1589","LU0320764599.SGD","BK1583","LU0456846285.SGD","LU1242518931.SGD","LU0348735423.USD","IE00BPRC5H50.USD","LU0516422440.USD","SURI","APXH","LU0039217434.USD","IE00B5MMRT66.SGD","LU0516422952.EUR","LU1046422090.SGD","LU0516423091.SGD","03759","LU0043850808.USD","LU0359202008.SGD","LU0029874061.USD","XBIX","LU1242518857.USD","BBC","LU2495084118.USD","02359","LU1880383366.USD","IE00B543WZ88.USD","LU2242644610.SGD","LU1719994722.HKD","LU1969619763.USD","SG9999002562.SGD","LU1997245094.SGD","LU0516422366.SGD","LFSC","LU0456842615.SGD","LU0979878070.USD","LU0823426308.USD","FHLC","LU1794554557.SGD","LU0327786744.USD","LU0456827905.SGD","BK1141","LU1251922891.USD","LU0348767384.USD","LU0348825331.USD","LU1688375341.USD","LU0052750758.USD","LU2488822045.USD","LU1808992512.USD","LU0823426480.USD","LU1303224171.USD","LU2039709279.SGD","LU0417516902.SGD","BK0216","PSCH","LU1720050803.USD","LU0700851271.USD","BK1521","LU0140636845.USD","LU0181495838.USD","LU0326950275.SGD","IBRN","LU0516423174.USD","603259"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659926188","title":"Outlook Therapeutics Ends ATM Prospectus Amid Ongoing Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2659926188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659926188?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:37","pubTimestamp":1786567029,"startTime":"0","endTime":"0","summary":"The latest update is out from Outlook Therapeutics ( ($OTLK) ). On July 24, 2026, Outlook Therapeutics announced U.S. FDA approval of LYTENAVA (bev...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/outlook-therapeutics-ends-atm-prospectus-amid-ongoing-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","GNMX","BK4139","IDNA","FRTY","TECB","NVIB","IBB","LENZ","IEIH","IYH","MRNX","XLVX","BMED","BK4007","RSPH","LFSC","MRNY","BK4585","LABU","SYNB","BBP","PSCH","TBXU","MEDI","PINK","BK4539","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659188699","title":"Moderna Inc. Stock Rises 5.1%, Outperforms Peers","url":"https://stock-news.laohu8.com/highlight/detail?id=2659188699","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659188699?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:34","pubTimestamp":1786566840,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Moderna Inc. rallied 5.1% to $63.67 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index rising 0.5% to 26,588.49 and the Dow Jones Industrial Average remaining mostly unchanged at 53,770.27.This was the stock's fourth consecutive day of gains.Moderna Inc. closed 25.6% below its 52-week high of $85.60, which the company reached on July 6th.The stock outperformed some of its peers, as Johnson & Johnson rose 0.4% to $260.86, Pfizer Inc. fell 1.2% to $26.31, and Gilead Sciences Inc. rose 0.07% to $135.87.Trading volume totaled 6.0 million, compared to the 50-day average of 7.3 million.Data source: Dow Jones Market Data, FactSet","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDI","LU0965508806.USD","LU1057294990.SGD","LU1066051498.USD","BK4550","BK4551","BK4585","LU2112291526.USD","LU1037948897.HKD","TMED","BMED","BIB","LU1585245621.USD","MRNX","GILD","LU0289739699.SGD","IBBQ","LU1037948541.HKD","LU1674673691.USD","BK4566","LU0320765992.SGD","TBXU","LGHT","BBH","LU2087621335.USD","LU1061106388.HKD","LU1430594728.SGD","IE00BKVL7J92.USD","LU0823416689.USD","LU1934455194.USD","IDNA","WDNA","IE0002270589.USD","GNOM","BK4588","LU0882574055.USD","IE00B19Z3581.USD","MRNA","LU0889565916.HKD","LU2324357040.USD","MRNY","IE00BZ1G4Q59.USD","LU1674673428.USD","LU1023059063.AUD","BK4501","BK4139","IE00BSNM7G36.USD","SG9999015978.USD","BK4532","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659907259","title":"Press Release: Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659907259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659907259?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:05","pubTimestamp":1786565100,"startTime":"0","endTime":"0","summary":"-- On track for September 2026 top-line results from Phase 2b clinical trial.  evaluating laromestrocel as a potential adjunct treatment for. hypoplastic left heart syndrome , a rare pediatric disease and. -- Longeveron selected as a Finalist and Milestone 2 Awardee for the XPRIZE. Healthspan competition based on published clinical trial results which. indicated laromestrocel increased 6-minute walk distance in patients with. -- Three new independent Directors join Longeveron's Board of Directors. laromestrocel as a potential adjunct therapy for HLHS are anticipated in. -- In May, the Company announced that the U.S. Food and Drug Administration.  held a Type C meeting in late March 2026 focused on the ELPIS II. Phase 2b clinical trial and upcoming data readout.-- Also in May, the Company announced that the independent Data Monitoring. Committee  completed its final prespecified data review for ELPIS II. Phase 2b clinical trial . The DMC performed a risk-benefit. assessment, indicated n","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4189","IND","R","BK4022","LGVN","BK4139","GDOC","HYLG","MEDX","BK4081","BK4132","EMA","NVIB","BK4232","IDNA","DMC","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658290503","title":"Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2658290503","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658290503?lang=en_us&edition=fundamental","pubTime":"2026-08-12 23:02","pubTimestamp":1786546971,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals  has multiple potential catalysts coming from its portfolio that provide a net positive risk-reward profile for the company, RBC Capital Markets said in a Wednesday note.The company is expected to present results from its phase 1 study of VX-828 in patients with cystic fibrosis in H2, with a positive readout potentially strengthening its competitive advantage in the space, RBC analysts said.Favorable data will likely result in modest upside, while unfavorable data will likely lead to little downside, the analysts added.Meanwhile, approval by the US Food and Drug Administration for Vertex's povetacicept in immunoglobulin A nephropathy, with a PDUFA date of Nov. 30, 2026, is likely due to strong interim phase 3 results, the analysts said.They said that the drug's differentiated profile could make it the preferred choice of most doctors.With Sionna Therapeutics  failing to demonstrate significant sweat chloride improvements as an add-on to Trikafta, one of the more ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","LU0058720904.USD","GNMX","BK4139","IDNA","IE00B19Z9P08.USD","LU0079474960.USD","LU2237438978.USD","IBB","IE00B19Z3B42.SGD","LU0109394709.USD","LU0061475181.USD","SION","LU0889565916.HKD","LU0566484027.USD","LU1430594728.SGD","PBE","LU2362541513.USD","LU2324357040.USD","BK4023","IE00B19Z9Z06.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4567","VERX","VRTX","LU2362540622.SGD","LU1674673691.USD","SGXZ57979304.SGD","IE00BZ9MQY76.HKD","LU1778281490.HKD","LU2417539215.USD","IE00B19Z3581.USD","BK4585","IBBQ","BBH","LU2456880835.USD","SG9999013999.USD","LU1815336091.USD","TBXU","LU1559883803.SGD","LU0417517546.SGD","LU1069344957.HKD","IE00BFTCPJ56.SGD","LU2362541273.HKD","BIB","IE00B2B36J28.USD","BK4532","LU1093756325.SGD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658086429","title":"Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2658086429","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658086429?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:30","pubTimestamp":1786537800,"startTime":"0","endTime":"0","summary":"Contrasting Science with Revolution Medicines and ErascaMELBOURNE, Australia, Aug.  12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutica","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/12/3343641/0/en/propanc-biopharma-highlights-differentiated-proenzyme-therapy-prp-as-a-potential-therapy-of-choice-against-ras-driven-cancers.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861215975.USD","LU1861219969.SGD","CANC","IE00BZ199S13.USD","PTH","ON","BBH","LU1861214812.USD","RVMD","LU1854104046.USD","LU2298322129.HKD","LU1861220033.SGD","LU0889565916.HKD","IE00BJJMRZ35.SGD","LU2357305700.SGD","IE0002141913.USD","ERAS","CHH","LU0320765992.SGD","LU1548497426.USD","LU0124384867.USD","LU1720051017.SGD","LU1983260115.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4512","BK4139","LU1720051108.HKD","IE00BFMHRM44.USD","IE00BJT1NW94.SGD","IDNA","BK4142","BK4539","LU1978683503.SGD","IE0009355771.USD","BK4585","IE00BD6J9T35.USD","BK4141","LU0109394709.USD","BK4588","LU0724618433.USD","LU0348723411.USD","BK4605","PDX","LU1854103824.USD","LU2360107325.USD","IE00B2B36J28.USD","IE0009354923.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972189","title":"Press Release: Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972189","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972189?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:00","pubTimestamp":1786536000,"startTime":"0","endTime":"0","summary":"double-blind, placebo-controlled global trial evaluating two doses of. AP01 dosed twice daily in patients with progressive pulmonary fibrosis. . This 52-week trial is designed to assess safety and efficacy of. AP01, with a primary endpoint of change in lung function measured by. forced vital capacity . The study overenrolled beyond its target. enrollment of 375, with a total of 398 patients randomized into three. treatment cohorts. Topline data are anticipated in the second half of. -- In September 2026, the Company plans to present two abstracts at the ERS. Congress in Barcelona, Spain. The first poster will highlight data. modeling effective AP01 distribution throughout the target tissue in both. healthy and idiopathic pulmonary fibrosis  lungs. The second poster. will describe the integration of patient perspectives into clinical trial. design. Detailed poster session information will be provided in advance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","AVLN","IDNA","MEDX","BK4007","NVIB","HYLG","FVC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":11,"totalSize":240,"code":"91000000","status":"200"}]}}